

PFIZER INC
Form 8-K
April 29, 2019

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 25, 2019
PFIZER INC.
(Exact name of registrant as specified in its charter)

Delaware	1-3619	13-5315170
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
235 East 42nd Street		10017
New York, New York		(Zip Code)
(Address of principal executive offices)		
Registrant's telephone number, including area code:		
(212) 733-2323		

Not Applicable

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07 Submission of Matters to a Vote of Security Holders

(a) The Pfizer Inc. (the "Company") Annual Meeting of Shareholders was held on April 25, 2019.

(b) Shareholders voted on the matters set forth below.

1. The nominees for election to the Company's Board of Directors were elected to hold office until the Company's next Annual Meeting of Shareholders, based upon the following votes:

Nominee	Votes For	Votes Against	Abstentions	Broker non-vote
Ronald E. Blaylock	3,912,479	252,785,594	255	11,037,194
Albert Bourla	3,968,299	845,237,724	642	10,086,214
W. Don Cornwell	3,792,127	947,199,713	095	10,264,240
Joseph J. Echevarria	3,824,294	719,167,540	269	10,276,108
Helen H. Hobbs	3,960,013	945,333,120	500	8,974,658
James M. Kilts	3,856,874	668,135,060	973	10,175,455
Dan R. Littman	3,959,418	600,32,811,206		9,881,290
Shantanu Narayen	3,948,229	994,43,833,811		10,047,291
Suzanne Nora Johnson	3,878,704	857,114,112,491		9,293,748
Ian C. Read	3,948,620	315,41,924,275		11,566,505
James C. Smith	3,941,173	326,50,720,278		10,217,492

2. The proposal to ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the 2019 fiscal year was approved based upon the following votes:

Votes for approval	4,701,180,439
Votes against	175,867,847
Abstentions	12,887,303
Broker non-votes	n/a

3. The proposal to approve, on an advisory basis, the compensation of the Company's Named Executive Officers was approved based upon the following votes:

Votes for approval	3,764,667,463
Votes against	200,933,424
Abstentions	36,509,563
Broker non-votes	887,836,749

4. The proposal to approve the Pfizer Inc. 2019 Stock Plan was approved based upon the following votes:

Votes for approval	3,439,109,067
Votes against	540,573,214
Abstentions (Have the same effect as a vote against this proposal under New York Stock Exchange rules)	22,428,815
Broker non-votes	887,836,749

5. The shareholder proposal regarding right to act by written consent was not approved based upon the following votes:

Votes for approval	494,345,288
Votes against	3,478,617,639
Abstentions	29,142,088
Broker non-votes	887,836,749

6. The shareholder proposal regarding report on lobbying activities was not approved based upon the following votes:

Votes for approval	1,179,442,668
Votes against	2,780,664,931
Abstentions	42,003,373
Broker non-votes	887,836,749

7. The shareholder proposal regarding independent chair policy was not approved based upon the following votes:

Votes for approval	1,067,318,698
Votes against	2,909,751,046
Abstentions	25,039,598
Broker non-votes	887,836,749

8. The shareholder proposal regarding integrating drug pricing into executive compensation policies and programs was not approved based upon the following votes:

Votes for approval	1,132,357,518
Votes against	2,814,700,448
Abstentions	55,053,129
Broker non-votes	887,836,749

(c) Not applicable
(d) Not applicable

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.

PFIZER INC.

Dated: April 29, 2019 By: /s/ Margaret M. Madden
Margaret M. Madden
Title: Senior Vice President & Corporate Secretary
Chief Governance Counsel